One-carbon therapeutics wins ELAVITY Pitch Event

by admin
juni 28, 2022

Our team is happy and proud to have been voted as the winner for pitching our MTHFD1/2 inhibitor program.

https://www.linkedin.com/feed/update/urn:li:activity:6948268990171365376

Rekommenderade artiklar

One-carbon Therapeutics announces oversubscribed private placement financing of SEK 153 million (€13.9 million)

Solna, Sweden, December 1, 2025. One-carbon Therapeutics AB, a clinical-stage

One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors

Stockholm, Sweden. November 17th, 2025. One-carbon Therapeutics AB, a clinical-stage biotechnology

One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe

One-carbon therapeutics AB is discussing the ODIN trial with several